Ressources
-
STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
Case study
Search Results
Search across news, resources and pages to quickly find relevant content on our site.
Technical Notes
Discovering specific effects on food intake: Satiation profiling and pica assessment help identify potential anti-obesity agents.
Technical Notes
Measure glucose tolerance routes in rodents, assess insulin sensitivity, and test antidiabetic potential with Sitagliptin in insulin-resistant models.
Technical Notes
Explore the mechanisms of satiety and reduced food intake through gastric emptying rate assessment. Our direct and indirect models offer insights into drug effects. Validate with clinical opioid agonist loperamide.
Technical Notes
Explore the Adriamycin-induced Model of Focal Segmental Glomerulosclerosis (FSGS) and Fibrosis. Discover how this rodent model mimics human proteinuric kidney disease, offering quick induction of renal injury and a customizable study design for prevention or reversal of the phenotype. Witness the demonstrated effectiveness of Enalapril in preventing and partially reversing the adriamycin-induced phenotype. Unravel new insights into FSGS research today.
Technical Notes
Revolutionary GN research: anti-GBM rodent model mimics human GN, showcasing rapid inflammation, severe proteinuria & effective treatments.
Technical Notes
Zucker diabetic fatty (ZDF-Leprfa/Crl) rats exhibit obesity, insulin resistance, impaired glucose tolerance, hypertension, and renal…
Technical Notes
Non-alcoholic liver disease, or NASH, is the manifestation of metabolic disorder in the liver. The…
Technical Notes
Non-alcoholic steatohepatitis (NASH) and liver fibrosis are associated with an increased risk of developing hepatocellular…
Technical Notes
Explore NASH & fibrosis in ob/ob H-FFC mouse model. Validate treatments for liver disease, obesity, insulin resistance, and co-morbidities.
Technical Notes
Advancing Schizophrenia Treatment with potent assays. Breakthrough compounds and hyperactivity reversal. Discover more.
Technical Notes
Sygnature has successfully developed and validated a new rat model of binge-eating disorder. Rats…
Technical Notes
To explore potential therapeutic interventions for achieving abstinence, we can utilise the self-administration model in…
Technical Notes
Withdrawal Symptom Relief: Our rat model assesses drug dependence & withdrawal profiles. Explore potential therapeutics now.
Technical Notes
To explore therapeutic interventions targeted at reducing the probability of relapse to drug taking following…
Technical Notes
Explore Locomotor Sensitization in Substance Use Disorders: Our mouse model assesses addiction progression and compound effects.
Technical Notes
Elevate drug discovery with ex vivo receptor binding at Sygnature Discovery. Uncover target engagement & receptor insights for effective compounds.
Technical Notes
We offer a wide range of behavioural and physiological assays that can be used to…
Technical Notes
Intravenous self-administration in rats is an extremely reliable predictor of the risk of abuse by…
Technical Notes
Explore Drug Discrimination: Rat interoceptive cues distinguish CNS drugs. Vital in CNS-active compound assessment for psychoactive effects.
Technical Notes
Withdrawal symptoms, indicative of physical dependence can occur following the abrupt cessation of sub-chronic dosing…
Technical Notes
Sygnature provides a variety of models to compare the pharmacological profiles of novel drugs…
Support
Can't find what you're looking for?
Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.
